<DOC>
	<DOCNO>NCT00891813</DOCNO>
	<brief_summary>The purpose study observe effectiveness safety use low initial dose regime ( iPTH/100 ) chronic kidney disease patient secondary hyperparathyroidism ( PTH &gt; 300pg/mL ) require dialysis least 3 time per week .</brief_summary>
	<brief_title>Effectiveness Safety IV Zemplar Patients Hemodialysis With Secondary Hyperparathyroidism Using iPTH/100 Initial Dose</brief_title>
	<detailed_description>The study carry three dialysis center Peru . Each patient enrol study follow 6 month period time inclusion . Study visit occur Baseline Weeks 4 , 8 , 12 24 study .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hypercalcemia</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>Patients &gt; =18 year old secondary hyperparathyroidism ( PTH &gt; 300pg/mL , measure last 2 week ) . Patients hemodialysis require start therapy IV paricalcitol ( de novo ) . Patients attend 3 hemodialysis session per week . Patients sign informed consent approve Ethics Committee . If individual capable give his/her consent , obtain next kin his/her legal representative , accord local law regulation . The decision initiate treatment upon investigator decision treat patient IV paricalcitol must base inclusion patient study way . The decision treat patient IV paricalcitol take prior ask patient participate study . Patients concomitant clinical condition , accord investigator 's opinion , might impede adequate assessment treatment response . Patients severe hyperparathyroidism ( PTH &gt; 3000pg/mL ) . Patients serum calcium level great equal 10.5mg/dL , phosphorus great equal 6.5mg/dL , Calcium X Phosphorus product 65 ( measure least 2 week study ) . Patients neoplastic disease . Pregnant lactating woman . Known hypersensitivity and/or toxicity vitamin D metabolites and/or ingredient product . Having participate another study investigational product device within previous 30 day plan participate another study within period time actual study . Use vitamin D analogue last 3 month prior inclusion study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
</DOC>